Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.

The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.

Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult ...

Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold for the next 3 years. On March 31, Eli Lilly ...

Shares of Centessa Pharmaceuticals plc skyrocketed more than 44% Tuesday after the clinical-stage biotech announced it would ...

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...

Eli Lilly (NYSE:LLY) has received U.S. FDA approval for Foundayo, the first once daily oral GLP 1 pill for obesity, and has ...

Lilly acquires Centessa for $6.3B, gaining an orexin receptor agonist pipeline targeting narcolepsy and other sleep-wake ...

By Sneha S K March 31 (Reuters) - Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at up to ...

INDIANAPOLIS – Eli Lilly and Company will acquire Centessa Pharmaceuticals, a United Kingdom-based company researching ...

Centessa, which has headquarters in the U.K. and in Boston, has focused on disorders that leave people struggling to stay ...